Prenetics Global Limited (NASDAQ:PRE) Short Interest Down 24.7% in January

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 32,600 shares, a drop of 24.7% from the January 15th total of 43,300 shares. Based on an average daily trading volume, of 14,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 0.4% of the shares of the company are sold short.

Prenetics Global Stock Performance

Prenetics Global stock traded down $0.01 during mid-day trading on Tuesday, reaching $5.40. 1,646 shares of the company were exchanged, compared to its average volume of 18,153. Prenetics Global has a twelve month low of $2.85 and a twelve month high of $7.84. The firm's 50-day simple moving average is $5.58 and its two-hundred day simple moving average is $5.02. The firm has a market cap of $65.89 million, a PE ratio of -1.35 and a beta of -0.31.

Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its quarterly earnings results on Wednesday, November 27th. The company reported ($0.84) EPS for the quarter. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. As a group, equities research analysts anticipate that Prenetics Global will post -3.3 EPS for the current year.

Hedge Funds Weigh In On Prenetics Global

An institutional investor recently bought a new position in Prenetics Global stock. Quinn Opportunity Partners LLC purchased a new position in shares of Prenetics Global Limited (NASDAQ:PRE - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,339 shares of the company's stock, valued at approximately $72,000. Quinn Opportunity Partners LLC owned approximately 0.10% of Prenetics Global as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 25.01% of the company's stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $9.00 price objective on shares of Prenetics Global in a research report on Thursday, January 16th.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.